AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status
Related Articles
Anumana’s Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag
Fierce Biotech: For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms designed to catch hard-to-spot…{post_date: F d, Y}
Mayo Clinic launches two joint ventures to build, commercialize diagnostic AI tools
Med City News: Mayo Clinic struck two joint ventures to develop and commercialize AI diagnostic tools. The idea was to develop algorithms to support clinicians’ decisions, starting with a suite…{post_date: F d, Y}
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG Data
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG DataCAMBRIDGE, Mass, June 27, 2024 Anumana, a leading AI-driven health technology company…{post_date: F d, Y}
Anumana expands AI cardiac care platform with support from Boston Scientific
Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific. Read more on massdevice.com{post_date: F d, Y}